Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nucala Among Flurry Of New Respiratory Products On Indian Horizon

Executive Summary

Novel asthma/COPD drugs, including GlaxoSmithKline’s biologic therapy Nucala, are on the horizon in India, set to expand treatment options in the competitive segment. But pricing is expected to be key in pushing uptake, and health care delivery in asthma/COPD in India remains rather sub-optimal, notwithstanding the interest around new launches.

Advertisement

Related Content

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123548

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel